GAM Holding’s Avadel Pharmaceuticals AVDL Stock Holding History

GAM Holding’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-59,700	Closed	-$620K	–	1046
2016 Q4	$620K	Hold	59,700	–	–	0.01%	705
2016 Q3	$740K	Sell	59,700 -59,700	-50%	-$780K	0.01%	658
2016 Q2	$1.28M	Buy	119,400 +59,700	+100%	+$637K	0.02%	614
2016 Q1	$659K	Hold	59,700	–	–	0.01%	671
2015 Q4	$729K	Hold	59,700	–	–	0.01%	767
2015 Q3	$974K	Buy	+59,700	New	+$1.31M	0.02%	699

Other funds holding AVDL

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

GAM Holding's AVDL Position: Q1 2017 in Review

GAM Holding sold out of Avadel Pharmaceuticals (AVDL) in Q1 2017, closing a stake of 59,700 shares — an estimated $620K sold.

GAM Holding first reported a position in AVDL in Q3 2015 and held it in 6 quarters. The position peaked at $1.28M in Q2 2016. 74 funds tracked by Wall St. Rank hold AVDL as of Q1 2017.

GAM Holding reported no remaining Avadel Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
GAM Holding sold 59,700 Avadel Pharmaceuticals shares in Q1 2017, an estimated $620K.
GAM Holding first reported a position in Avadel Pharmaceuticals in Q3 2015 and held it in 6 quarters.
GAM Holding's Avadel Pharmaceuticals position peaked at $1.28M in Q2 2016.
74 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2017.

Based on GAM Holding's 13F filing for Q1 2017, filed 12 May 2017.